Alan M. Mendelsohn, MD, Executive Vice President and Chief Medical Officer at Timber Pharmaceuticals, gives an overview of congenital ichthyosis.
As Dr. Mendelsohn explains, congenital ichthyosis is a rare genetic skin disorder characterized by dry, thickened, and scaling skin. Individuals with this condition may experience limited range in motion, chronic itching, an inability to sweat, and increased risk of infections.
Currently, Timber Pharmaceuticals is focusing on two subtypes of this rare disease: the x-linked form which is more common in males than females, and autosomal recessive congenital (also known as lamellar) ichthyosis which is rarer overall. The company recently presented 7 abstracts at the 31st European Academy of Dermatology and Venereology Congress detailing positive clinical data from the completed phase 2b CONTROL study of TMB-001. TMB-001 is a topical isotretinoin that is currently under investigation for the treatment of congenital ichthyosis.
